

### Global Longlife Hospital and Research Limited

Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380 054, Gujarat, India

# AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED ON 31.03.2022

No.   Particulars   Audited   Unaudited   Audited   Audited   Audited   Audited   Audited   Audited   Other Income   16.10   6.69   22.79   6   6   1   1   1   1   1   1   1   1			(R	(Rs. in Lakhs except per share data)		
Revenue from Operations	100000000000000000000000000000000000000	Particulars		TOTAL DESIGNATION OF THE PROPERTY OF THE PROPE		Year ended 31.03.2021
Revenue from Operations			Audited	Unaudited	Audited	Audited
Other Income   16.10   6.69   22.79   56		Revenue from Operations				3,270.26
Total Income (1+II)		Other Income				6.32
II   Expenses	I	Total Income (I+II)				3,276.59
Cost of Materials consumed   Purchase of Stock-in-Trade   91.36   276.15   367.51   720	II			-,,,,,,,,	5,500.000	0,27 0.00
Cost of Materials consumed			628.03	736.15	1.364.18	1,285.04
Changes in inventories of finished goods, work in progress and stock in trade   S.26 (15.32) (7.08)   138   and stock in trade   Employee benefits expenses   235.32   170.74   406.06   341   341   341   342   342   343   343   344   344   344   345					.,,	1,200.01
Changes in inventories of finished goods, work in progress and stock in trade  Employee benefits expenses 235.32 170.74 406.06 341  Finance Costs 130.70 9.19 139.89 243  Depreciation and amortisation expenses 55.84 57.53 114.37 130  Other Expenses 198.46 149.90 348.37 241  Total Expenses 1,349 1,384 2,733.32 3,100  III Profit/(Loss) before exceptional items and tax (I - II) (45.58) 616.59 571.01 175  IV Exceptional Items		Purchase of Stock-in-Trade	91.36	276.15	367.51	720.30
Finance Costs   130.70   9.19   139.89   243		and stock in trade			•	138.27
Finance Costs   130.70   9.19   139.89   243		Employee benefits expenses	235.32	170.74	406.06	341.63
Depreciation and amortisation expenses   56.84   57.53   114.37   130		A CONTRACTOR OF THE CONTRACTOR				243.18
Other Expenses   198.46   149.90   348.37   241						130.63
Total Expenses						241.78
III   Profit/(Loss) before exceptional items and tax (I - II)   (45.58)   616.59   571.01   175     IV   Exceptional Items		Total Expenses				3,100.83
V   Profit/(Loss) before tax (III - IV)	III	Profit/(Loss) before exceptional items and tax (I - II)		The Chicagolican Control		175.76
VI Tax Expense a) Current tax b) Deferred tax c) Excess/(Short) Provision Of Earlier Years  VII VI) Net Profit/(Loss) from ordinary activities after tax (V - VI) VI) Net Profit/(Loss) from discontinued operations before tax  IX Tax Expense of discontinued operations after tax (VII + X) VII Net Profit/(Loss) from discontinued operations after tax (VIII - IX) XI Net Profit/(Loss) for the period after tax (VII + X) VII Other Comprehensive Income / (Expenses) - (Net of Tax) XII Total Comprehensive Income attributable to: a) Owner b) Non-controling Interest XV Paid-up Equity Share Capital (Face Value of Rs.10 each) XVI Earning per equity share (for continuing operation) (a) Basic(Rs.) (b) Diluted(Rs.) XVII EPS (for discontinue & continuing operation) (a) Basic(Rs.) (CPITA)	IV	Exceptional Items	EANTH-		_	
A Current tax  a) Current tax  b) Deferred tax  c) Excess/(Short) Provision Of Earlier Years  118.32  104  104  105  105  106  107  107  107  108  108  108  108  108	V	Profit/(Loss) before tax (III - IV)	(45.58)	616.59	571.01	175.76
b) Deferred tax c) Excess/(Short) Provision Of Earlier Years  VII VI)  Net Profit/(Loss) from ordinary activities after tax (V - VI)  Net Profit/(Loss) from discontinued operations before tax  IX Tax Expense of discontinued operations  X Net Profit/(Loss) from discontinued operations after tax (VIII - IX)  XI Net Profit/(Loss) for the period after tax (VII + X)  Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII Total Comprehensive Income (XI + XII)  XIV Total Comprehensive Income attributable to: a) Owner b) Non-controling Interest  XV Paid-up Equity Share Capital (Face Value of Rs. 10 each)  XV Paid-up Equity Share (for continuing operation)  (a) Basic(Rs.)  (b) Diluted(Rs.)  XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)	VI	Tax Expense				170.70
b) Deferred tax c) Excess/(Short) Provision Of Earlier Years c) Excess/(Short) Provision Of Earlier Years  VII Net Profit/(Loss) from ordinary activities after tax (V-VI) Net Profit/(Loss) from discontinued operations before tax  IX Tax Expense of discontinued operations X Net Profit/(Loss) from discontinued operations after tax (VIII - IX) XI Net Profit/(Loss) for the period after tax (VII + X)  Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII Total Comprehensive Income (XI + XII) XIV Total Comprehensive Income attributable to: a) Owner b) Non-controling Interest  XV Paid-up Equity Share Capital (Face Value of Rs.10 each) XVI Earning per equity share (for continuing operation) (a) Basic(Rs.)  (b) Diluted(Rs.)  XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)  CEPTA  118.32 (28		a) Current tax	95.30		95.30	
c) Excess/(Short) Provision Of Earlier Years  VII VI		b) Deferred tax	118.32		100000000000000000000000000000000000000	(28.94)
VII   Net Profit/(Loss) from ordinary activities after tax (V - VI)   (259.20)   616.59   357.39   204		c) Excess/(Short) Provision Of Earlier Years		-		(20.01)
IX Tax Expense of discontinued operations  X Net Profit/(Loss) from discontinued operations after tax (VIII - IX)  XI Net Profit/(Loss) for the period after tax (VII + X)  XII Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII Total Comprehensive Income (XI + XII)  XIV Total Comprehensive Income attributable to:  a) Owner  b) Non-controling Interest  XV Paid-up Equity Share Capital (Face Value of Rs.10 each) 700.00 700.00 700.00 700  XVI Earning per equity share (for continuing operation)  (a) Basic(Rs.) (3.70) 8.81 5.11 2.11  XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.) (3.70) 8.81 5.11 2.11  EPS (for discontinue & continuing operation)			(259.20)	616.59		204.70
X   Net Profit/(Loss) from discontinued operations after tax (VIII - IX)  XI   Net Profit/(Loss) for the period after tax (VIII + X)  XII   Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII   Total Comprehensive Income (XI + XII)  XIV   Total Comprehensive Income attributable to:  a) Owner  b) Non-controling Interest  XV   Paid-up Equity Share Capital (Face Value of Rs.10 each)   700.00   700.00   700.00   700  XVI   Earning per equity share (for continuing operation)  (a)   Basic(Rs.)   (3.70)   8.81   5.11   2.11	VIII	Net Profit/(Loss) from discontinued operations before tax				
X   Net Profit/(Loss) from discontinued operations after tax (VIII - IX)  XI   Net Profit/(Loss) for the period after tax (VIII + X)  XII   Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII   Total Comprehensive Income (XI + XII)  XIV   Total Comprehensive Income attributable to:  a) Owner  b) Non-controling Interest  XV   Paid-up Equity Share Capital (Face Value of Rs.10 each)   700.00   700.00   700.00   700  XVI   Earning per equity share (for continuing operation)  (a)   Basic(Rs.)   (3.70)   8.81   5.11   2.11	IX	Tax Expense of discontinued operations				
XI Net Profit/(Loss) for the period after tax (VII + X)  XII Other Comprehensive Income / (Expenses) - (Net of Tax)  XIII Total Comprehensive Income (XI + XII)  XIV Total Comprehensive Income attributable to:  a) Owner  b) Non-controling Interest  XV Paid-up Equity Share Capital (Face Value of Rs.10 each) 700.00 700.00 700.00 700.00  XVI Earning per equity share (for continuing operation)  (a) Basic(Rs.) (3.70) 8.81 5.11 2.11  XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.) (3.70) 8.81 5.11 2.11	x	Net Profit/(Loss) from discontinued operations after				
XIII Total Comprehensive Income (XI + XII)  XIV Total Comprehensive Income (XI + XII)  XIV Total Comprehensive Income attributable to:  a) Owner  b) Non-controling Interest  XV Paid-up Equity Share Capital (Face Value of Rs.10 each)  XVI Earning per equity share (for continuing operation)  (a) Basic(Rs.)  (b) Diluted(Rs.)  XVI Earning per equity share (for discontinued operation)  XVII Earning per equity share (for discontinued operation)  XVII Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)						
XIV   Total Comprehensive Income attributable to:   a) Owner		Other Comprehensive Income / (Expenses) - (Net of Tax)				
XIV   Total Comprehensive Income attributable to:   a) Owner	XIII	Total Comprehensive Income (XI + XII)			,	
a) Owner   b) Non-controling Interest   XV   Paid-up   Equity   Share   Capital   (Face   Value   of   Rs. 10   each)   700.00   700.00   700.00   700.00   700.00   XVI   Earning   per   equity   share   (for continuing   operation)   (3.70)   8.81   5.11   2.1   (5.11)   Earning   per   equity   share   (for discontinued   operation)   XVI   Earning   per   equity   share   (for discontinued   operation)   XVI   EPS   (for discontinue & continuing   operation)   (a)   Basic(Rs.)   CRITAL	XIV	Total Comprehensive Income attributable to:				
XV				-		
XV   Paid-up Equity Share Capital (Face Value of Rs.10 each)   700.00   700.00   700.00   700.00   XVI   Earning per equity share (for continuing operation)   (a)   Basic(Rs.)   (3.70)   8.81   5.11   2.5   (5.11)   Earning per equity share (for discontinued operation)   XVI   Earning per equity share (for discontinued operation)   XVI   EPS (for discontinue & continuing operation)   (a)   Basic(Rs.)   CRITAL		b) Non-controling Interest				
XVI   Earning per equity share (for continuing operation)   (a)   Basic(Rs.)   (3.70)   8.81   5.11   2.5	XV	Paid-up Equity Share Capital (Face Value of Rs.10 each)	700.00	700.00	700.00	700.00
(a) Basic(Rs.) (3.70) 8.81 5.11 2.  (b) Diluted(Rs.) (3.70) 8.81 5.11 2.  XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)		Earning per equity share (for continuing operation)				7 00.00
(b) Diluted(Rs.) (3.70) 8.81 5.11 2.13 XVI Earning per equity share (for discontinued operation) XVII EPS (for discontinue & continuing operation) (a) Basic(Rs.)		(a) Basic(Rs.)	(3.70)	8.81	5.11	2.92
XVI Earning per equity share (for discontinued operation)  XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)	-					2.92
XVII EPS (for discontinue & continuing operation)  (a) Basic(Rs.)	IVX	Earning per equity share (for discontinued operation)	` /		-	2.02
(a) Basic(Rs.)	XVII	EPS (for discontinue & continuing operation)				
(b) Diluted(Rs.)						
	(	(b) Diluted(Rs.)				



A division of Global Longlife Hospital & Research Ltd.

For, Global Longlife Hospital and Research Limited

Ohruv Jani Managing Director

DIN: 03154680

Date: 30.05.2022 Place: Ahmedabad


Notes:

The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held May 30, 2022

2 Previous year's/period's figure have been regrouped/rearranged wherever necessary.

4 The company had used the fund of Initial Public offer as stated in the prospectus of the company

Since the company was listed on May 04, 2022 and submitting the financial result first time, The figures of the half year ended March 31, 2021 is not provided.





A division of

Global Longlife Hospital & Research LtdGlobal Longlife Hospital and Research Limited

Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380 054, Gujarat, India

#### Statement of Assets and Liabilities

(Rs. in Lakhs except per share data)

	Particulars	As At 31.03.2022	As At 31.03.2021
		Audited	Audited
	ASSETS	TAMATECA .	Addited
	Non-current assets		
	(a) Property, plant and equipment	1,670.87	1,745.50
	(b) Capital work-in-progress	1,0,0,0,	1,745.50
	(c) Goodwill		
	(d) Other intangible assets	0.44	0.47
	(e) Intangible assets under development		0.17
	(e) Financial assets		
	i. Investments	10.00	10.00
	ii. Loans		10.00
	iii. Others		
	(f) Deferred tax assets (Net)	257.20	375.52
	(f) Other non-current assets	324.10	376.13
	Total non-current assets	2,262.61	2,507.63
	Current assets		2,007100
	(a) Inventories	88.27	81.21
	(b) Financial assets		
	i. Investments	10.26	37.02
	ii. Trade receivables	890.72	784.08
	iii.Cash and cash equivalents	21.83	44.00
	iv.Bank balances other than (iii) above		
	v. Loans	111.42	221.37
	vi. Others		221.5
	(c) Current tax Assets (Net)	5.0	
	(d) Other current assets	12.29	2.09
	Total current assets	1,134.80	1,169.77
	Total assets	3,397.41	3,677.40
	EQUITY AND LIABILITIES		2,07711
	Equity		
	(a) Equity share capital	700.00	700.00
	(b) Other equity	996.22	667.70
	No	1,696.22	1,367.70
1	LIABILITIES	,,,,,,,,,	1,507.70
	Non-current liabilities		
1	(a) Financial Liabilities	9	
	i. Borrowings	282.12	1,250.67
	ii. Trade Payables	202.12	1,230.07
	iii. Other financial liabilities		
	(b) Provisions	5.81	5.02



Globel Decifred can'the bilities (Net)td.		
(d) Other non-current liabilities	36.01	30.50
Total non-current liabilities	323.94	1,286.19
Current liabilities		
(a) Financial liabilities		
i. Borrowings	587.40	453.70
i. Trade payables		103.70
(a) Total outstanding dues of micro and small	×	*
enterprises		
(b) Total outstanding dues of creditors other than	427.86	326.24
micro and small enterprises		220.21
iii. Other financial liabilities		
(b) Other current liabilities	237.99	242.34
(c) Provisions	124.00	1.23
(c) Current Tax Liabilities (Net)		1.20
Total current liabilities	1,377.25	1,023.51
Total liabilities	1,701.19	2,309.71
Total equity and liabilities	3,397.41	3,677.40

Notes:

The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective

1 meetings held May 30, 2022

Previous year's/period's figure have been

- 2 regrouped/rearranged wherever necessary.

  The results for the Half Year and year ended March 31, 2022 are available on the website of BSE Limited on www.bseindia.com and on
- 3 company website on www.globalhospital.co.in

The company had used the fund of Initial Public

- 4 offer as stated in the prospectus of the company Since the company was listed on May 04, 2022 and submitting the financial result first time, The figures of the half year ended March 31, 2021 is
- 5 not provided.

For, Global Longlife Hospital and Research Limited

BODAKDEV

Dhruv Jani Managing Director DIN: 03154680

Date: 30.05.2022 Place: Ahmedabad



A division of Global Longlife Hospital & Research Ltd.

BODAKDEV

Global Longlife Hospital and Research Limited

Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380 054, Gujarat, India

# CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH 2022

	Particulars	2021 2022	[Amount in Lakh
		2021-2022	2020-202
	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before taxation and extraordinery items	571.01	175.7
	Adjustment for :-		77017
D	Depreciation and Amortization	114.37	130.6
L	ong Term Capital Loss	6.13	130.0
	Jon Cash Exp	57.58	57.5
Ir	nterest Income	(20.39)	(5.9
F	inance Costs	131.09	227.8
	sub-total	859.79	585.8
		007117	363.0
S	hort Term Capital Gain		
L	ong Term Capital Gain		
G	ain on Fair Valuation on Financial Instruments (MF)		
P	rovision written back		
In	nterest income	ALCOHOLD .	
	An alternative description of the second of		
0	perating Profit berfore working capital changes		
C	Change in working Capital:	A CONTRACTOR OF THE CONTRACTOR	
	djustment for Decrease (Increase) in operating assets		
T	rade receivables	(106.60)	
	ventories	(106.63)	(157.1
	ther current Assets	(7.06)	138.2
	djustment for (Decrease) Increase in opearting liabilities	(1.54)	343.7
T	rade payables		
	ther current liabilities	101.61	(218.7
		1.15	(4.3
51	nort Term Provision	28.26	
	ash Generated from Operations		
	irect tax Paid	(66.87)	
	come tax refund received		
Ca	ash Flow before extraordinary items		
	xtraordinary Items/Prior Period Items		u2
N	et cash from Operating Activities	942.46	. 687.6
B. N	ET CASH FLOW FROM INVESTMENT ACTIVITIES		
Pu	rchase of Property, Plant and Equipment	(47.54)	(4.2
Sa	ale of Property, Plant and Equipment	1.70	
	aturity of Term Deposits	26.77	
	pans given		
Ва	ank deposits not considered under Cash and cash equivalents		
(Ir	ncrease) / Decrease in Current - financial loans		
Lo	ong Term Capital Loss		
	ort Term Capital Gain		
	ong Territai Sein		



A division of Global Longlife Hospital & Research Ltd.

Y	20.39	5.98
Interest income  Net Cash from Investment Activities	1.32	1.75
C. CASH FLOWS FROM FINANCING ACTIVITIES  Repayment of Long Term Borrowings	(968.54)	(494.42)
Proceeds from Short Term Borrowings	133.70	-
Finance Cost Expense	(131.09)	(227.83)
Net Cash from financial activities	(965.94)	* (722.26
NET INCREASE /(-) DECREASE IN CASH AND CASH EQUIVALI	(22.16)	(32.86)
FOREIGN EXCHANGE RATE FLUCTUATION		
OPENING BALANCE IN CASH AND CASH EQUIVALENTS	44.00	76.86
CLOSING BALANCE IN CASH AND CASH EQUIVALENTS	21.83	44.00

For, Global Conglife Hospital and Research Limited

Ohruy Jani

Managing Director DIN: 03154680 Date: 30.05.2022 Place: Ahmedabad



Independent Auditors' Report on Annual Standalone Financial Results of Global Longlife Hospital and Research Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To the Board of Directors of Global Longlife Hospital and Research Limited

#### Opinion

We have audited the accompanying annual financial results of Global Longlife Hospital and Research Limited (hereinafter referred to as the "Company") for the year ended 31<sup>st</sup> March, 2022. attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"),

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards, and other accounting principles generally accepted in India, of the net loss and net profit and other financial information for the Half year and year ended 31<sup>st</sup> March, 2022.

#### **Basis of Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SA") specified under Section 143(10) of the Companies Act. 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

#### Management's and Board of Directors' Responsibilities for the Annual Financial Results

These accompanying annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these accompanying Half Yearly and Annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 183 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 183 of the Listing Regulation.

Head Off.: 503, 5th Floor, "PATRON", Opp. Kensville Golf Academy, Rajpath Club to S P Ring Road, Bodakdev, Ahmedabad - 380054 LLPIN: AAO-7574

Tel: 079 40394154 E-mail: ahd.office@karmallp.in

www.karmallp.in

AHMEDABAD

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the accompanying Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the accompanying annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these accompanying annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the accompanying annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
  that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible
  for expressing our opinion through a separate report on the complete set of financial statements on
  whether the company has adequate internal financial controls with reference to financial statements
  in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the accompanying financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the accompanying annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions

are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the accompanying annual financial results, including the disclosures, and whether the accompanying annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The accompanying annual financial results include the results for the half year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first Half year of the current financial year.

For, K A R M A & Co. LLP Chartered Accountants FRN No. 127544W/W100376

> CA Jignesh A. Dhaduk Designated Partner

> > M.No.129149

UDIN: 22129149AJWHVC7919

Place: Ahmedabad Date: 30/05/2022



Annexure-1

Letter No.: GLHRL/03/2022-23

Date: May 30, 2022

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

> SCRIPT CODE: 539692 ISIN: INE064T01018

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 33(3)(d) of the Listing Regulations, as amended from time to time, we hereby declare that Statutory Auditor of Global Longlife Hospital and Research Limited, M/s, KARMA & CO LLP., Chartered Accountants (Firm Registration Number: 127544W/W100376), have submitted their Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended March 31, 2022, as approved by the Board at its Meeting held on May 30, 2022.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

BODAKDEV

Dhruv Jani

Managing Director

DIN: 03154680

Details of Utilization of Issue Proceeds

Details of Utilization of Issue Proceeds

Statement of Utilization of Money raised through Initial Public offer of Equity Shares up to and as at May 30, 2022

Sr. No.	Object as stated in the Prospectus	Amount proposed to be utilized	Actual amount utilized	Unutilized Amount
1.	Acquire Land on Leasehold Basis	2,000.00	2000.00	-
2.	Repayment of Loan	1,480.00	1480.00	-
3.	General corporate purposes	1,070.00	480.00	590.00
4.	Public Issue Expense	350.00	350.00	-
	Total	4,900.00	4306.00	590.00

For, Global Longlife Hospital and Rease Ten Line

DIN: 03154680